文献速递瓣膜外科主动脉外科

去细胞化同种肺动脉移植物在Ross术后的功能障碍:多中心研究

Pulmonary homograft dysfunction after the Ross procedure using decellularized homografts-a multicenter study.
PubMed 文献 · J Thorac Cardiovasc Surg · 2020-07-22

基于加拿大Ross登记处2011至2019年466例使用去细胞化冷冻保存同种肺动脉移植物行Ross手术的患者,6年累积功能障碍发生率为11±2%,再干预累积发生率为3±1%。术后第一年风险最高,年龄<45岁是唯一独立危险因素。

要点

  • 去细胞化同种肺动脉移植物Ross术后6年功能障碍累积发生率11±2%。
  • 功能障碍以狭窄为主(93%),多沿管道发生(59%)。
  • 年龄<45岁是唯一独立危险因素(HR 3.1,95%CI 1.1-8.6,P=.03)。

核心结论

  • 使用去细胞化冷冻保存同种肺动脉移植物行Ross手术后功能障碍和再干预发生率低。
  • 术后第一年风险最高,年轻年龄是唯一独立危险因素。

研究设计与样本

  • 多中心回顾性队列研究,纳入2011至2019年466例连续患者(平均年龄47±12岁,73%男性),均使用去细胞化冷冻保存同种肺动脉移植物(SynerGraft SG)行Ross手术。
  • 中位随访2.2年(最长8.5年),随访完整率99%(1176患者年)。

主要发现

  • 6年累积功能障碍发生率为11±2%。
  • 功能障碍以狭窄最常见(28例,93%),形态学上59%沿管道发生。
  • 4例需同种移植物再干预,6年累积再干预发生率为3±1%。
  • 术后第一年瞬时风险最高(3.5%/年),之后降至<1%/年。
  • 年龄<45岁是唯一独立危险因素(HR 3.1,95%CI 1.1-8.6,P=.03)。

关键数值与推荐

  • 肺动脉同种移植物功能障碍定义为满足以下任一:峰值肺动脉压差≥30 mm Hg、肺动脉反流>2级或肺动脉同种移植物再干预。
  • 符合至少1项标准者30例,与其余436例比较。

临床怎么用

  • 去细胞化同种肺动脉移植物可用于Ross手术,术后第一年需密切监测功能障碍。
  • 年轻患者(<45岁)应加强随访,因其功能障碍风险较高。

局限性

  • 中位随访仅2.2年,长期结果有待进一步观察。
  • 为回顾性登记研究,可能存在选择偏倚和未测量混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Pulmonary homograft dysfunction is a limitation after the Ross procedure. Decellularized pulmonary homografts can potentially mitigate this complication. The aim of this study was to examine the incidence, predictors, progression, and morphology of pulmonary homograft dysfunction using data from the Canadian Ross Registry. METHODS: From 2011 to 2019, 466 consecutive patients (mean age: 47 ± 12 years, 73% male) underwent a Ross procedure using a decellularized cryopreserved pulmonary homograft (SynerGraft SG; CryoKife, Kennesaw, Ga). Pulmonary homograft dysfunction was defined as any of the following: peak pulmonary gradient ≥30 mm Hg, pulmonary regurgitation >2, or pulmonary homograft reintervention. Patients meeting ≥1 of these criteria (n = 30) were compared with the rest of the cohort (n = 436). Median follow-up is 2.2 years (maximum = 8.5 years) and 99% complete (1176 patient-years). RESULTS: The cumulative incidence of pulmonary homograft dysfunction was 11 ± 2% at 6 years. Pulmonary homograft stenosis was the most frequent presentation (n = 28 patients, 93%). Morphologically, stenosis occurred most often along the conduit (59%). Overall, 4 patients required homograft reintervention. At 6 years, the cumulative incidence of homograft reintervention was 3 ± 1%. The instantaneous risk was greatest in the first year after surgery (3.5%/year) and decreased to <1%/year thereafter. Patient age <45 years was the only independent risk factor associated with pulmonary homograft dysfunction (hazard ratio, 3.1, 95% confidence interval, 1.1-8.6, P = .03). CONCLUSIONS: The use of decellularized cryopreserved pulmonary homografts results in a low incidence of dysfunction and reintervention after the Ross procedure. The risk is greater in the first postoperative year. Younger age is the only independent risk factor for pulmonary homograft dysfunction.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Chauvette V, Bouhout I, Tarabzoni M, et al. Pulmonary homograft dysfunction after the Ross procedure using decellularized homografts-a multicenter study. J Thorac Cardiovasc Surg. 2020. PMID: 32888704. doi:10.1016/j.jtcvs.2020.06.139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。